Please assess the completion status of the following clinical trial:

Trial Title: Prostate Artery Embolization as a Treatment for Benign Prostatic Hyperplasia in Men With Prostates Larger Than 90 Grams

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patient has provided signed informed consent~* Patient is aged greater than or equal to 40 and less than or equal to 89 years of age~* Patient has a prostate size between 90g and 200g, as determined by MRI~* Patient has experienced lower urinary tract symptoms (LUTS) for at least 6 months prior to study enrollment~* Patient has an IPSS score of at least 13 at baseline~* Patient is either: refractory to medical treatment, contraindicated to medical treatment, OR refuses medical treatment~* Patient either: refuses surgical treatment OR is contraindicated for surgical treatment~* Patient meets ONE of the following criteria: baseline PSA \< 4.0ng/mL (no prostate biopsy required) OR baseline PSA \>/= 4 ng/mL AND a negative prostate biopsy (minimum 12 core biopsy) within the prior 12 months~Exclusion Criteria:~* History of prostate, bladder, or rectal cancer~* History of transurethral resection of the prostate (TURP), open prostate surgery, or radiofrequency or microwave therapies~* History of open bladder, rectosigmoid colon, or other pelvic surgery~* Patient is unwilling to discontinue alpha blockers 1 month after study treatment~* Patient is unwilling to discontinue 5-alph reductase inhibitors 1 month after study treatment~* Neurogenic bladder or other neurologic disorder impacting bladder function such as Parkinson's disease, multiple sclerosis, cerebral vascular accident or diabetes~* Any other confounding bladder or urethral pathology, including urethral stricture, bladder neck contracture, or bladder atonia~* Active prostatitis or urinary tract infection~* Cystolithiasis within the past 3 months~* Serum creatinine \> 1.7mg/dL~* Inability to discontinue oral anticoagulant 2-5 days prior to study treatment~* Coagulation disturbances not normalized by medical treatment~* Iodinated contrast allergy that, in the opinion of the Investigator, cannot be adequately premedicated~* Gelatin allergy~* Known severe peripheral vascular disease or major iliac arterial occlusive disease~* Interest in future fertility~* Clinically significant cardiac arrhythmia or other cardiac disease (including congestive heart failure), uncontrolled diabetes mellitus, clinically significant respiratory disease, or known immunosuppression~* Other condition that the Investigator believes puts the patient at risk for a complication during the procedure

- Gender: MALE
- Minimum Age: 40 Years
- Maximum Age: 89 Years
- Healthy Volunteers: f

Study Arms:
- Treatment arm (Type: EXPERIMENTAL): Patients will receive prostate artery embolization (PAE) with Embosphere Microspheres.

Based on this trial design, predict the completion outcome and termination type (if applicable).